Tên IUPAC: 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-m
Số EC: 691-729-9
Khối lượng phân tử: 4114
Công thức hoá học: C₁₈₇H₂₉₁N₄₅O₅₉
Số CAS: 910463-68-2

Thông tin khác

Mô tả thêm:

This industrial-grade Semaglutide (CAS 910463-68-2, C187H291N45O59), manufactured by Fujian Lumira Biotech, is a synthetic GLP-1 receptor agonist modified to resist DPP-4 degradation, extending its half-life to support once-weekly subcutaneous dosing; the supplier describes its mechanism as glucose-dependent insulin stimulation, glucagon suppression, delayed gastric emptying, and appetite reduction, and notes it is marketed globally under brand names including Ozempic, Rybelsus, and Wegovy for diabetes and weight management, with emerging evidence of cardiovascular benefit. It is distributed across North America, Europe, Asia, the Middle East, and Africa.